GlassScriptPhysician profile
Matthew S Mclean
NPI 1699086199
$14,122.84
in general payments reported to CMS, 2019-2025
68 companies · $3,062 in 2025
The $3,062 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,919 · 2020: $1,193 · 2021: $2,334 · 2022: $1,943 · 2023: $1,625 · 2024: $2,047 · 2025: $3,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,733.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,232.57 | 2021-2025 | |
| Ucb, INC. | $1,169.83 | 2019-2025 | Zilbrysq, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $943.02 | 2019-2025 | |
| Lundbeck LLC | $694.03 | 2020-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $623.26 | 2020-2025 | |
| Biogen, INC. | $559.54 | 2019-2025 | Tysabri, Vumerity |
| Eisai INC. | $547.01 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $542.03 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $519.38 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Allergan, INC. | $438.54 | 2019-2022 | |
| Pfizer INC. | $397.26 | 2021-2025 | |
| Argenx US, INC. | $367.73 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $312.84 | 2019-2025 | Aimovig |
| Neurocrine Biosciences, INC. | $230.59 | 2019-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $224.50 | 2021-2022 |
Show all 67 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.